Format

Send to

Choose Destination
Front Endocrinol (Lausanne). 2015 Aug 17;6:126. doi: 10.3389/fendo.2015.00126. eCollection 2015.

Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches.

Author information

1
Division of Endocrinology, Federal University of the State of Rio de Janeiro , Rio de Janeiro , Brazil.
2
Laboratory of Translational Endocrinology, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
3
Division of Endocrinology, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.

Abstract

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors derived from the chromaffin tissue. Diagnosis of these tumors is extremely important as they are linked to the hypertension syndrome with great cardiovascular morbidity and mortality. A great majority of PCCs and PGLs are sporadic and benign tumors; however, the classic idea of 10% exception of these features is changing. The description of new genes linked to familial forms of PCC/PGLs, such as succinate dehydrogenase (SDH) complex subunits, KIF1Bβ, EGLN1, TMEM127, and MAX, added to the well-known PCC familial syndrome (MEN2, VHL, and neurofibromatosis type 1) presents new challenges for diagnosis. In this review, we discuss the diversity of clinical and genetic approaches to this syndrome as well the diverse criteria that should guide genetic investigation.

KEYWORDS:

MEN2; VHL; neurofibromatosis; pheochromocytomas; succinate dehydrogenase

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center